Transcatheter aortic valve replacement (TAVR) has revolutionised the treatment of
patients with aortic stenosis (AS) over the last 15 years.[1] TAVR is a well-established
procedure for the treatment of patients considered high risk for open surgery.[2]
Results from the PARTNER (Placement of AoRTic traNscathetER) trial showed that inoperable
patients randomly assigned to TAVR, had a 20% reduction in all-cause mortality, as
well as hospitalisation, at one year compared to best medical management.[3]
The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic
Surgery (EACTS) 2017 guidelines for AS management recommend consideration for TAVR
in patients with severe symptomatic AS who are not suitable or deemed to be of high
risk for cardiac surgery.[4] The guidelines recommend that TAVR decisions are taken
by the ‘Heart Team’, including cardiologists, cardiothoracic surgeons and anaesthetists.
To aid decision making multidisciplinary teams (MDTs) can make use of risk scores.
Commonly used risk scores including Society of Thoracic Surgeons (STS) and EuroSCORE
II have been found to be inaccurate at predicting mortality and morbidity in TAVR
patients.[5],[6] This is felt to be related to the complexity of this subgroup of
patients, with multiple co-morbidities and frailty.[7]
Frailty is a recognised clinical entity, independent of age, co-morbidity and disability.
It is a defined as a state of reduced physiological reserve, and associated with an
increased susceptibility to poor healthcare outcomes.[8] Frailty has been shown to
result in worse post-operative recovery across surgical specialties.[9] Green, et
al.[10] identified increased mortality and higher rates of poor outcomes at one year
following a TAVR, in frail patients. However, such studies use complex frailty scores,
which are difficult and time consuming in real life situations. For example, Huded,
et al.[11] used a modified Fried frailty assessment that comprised of four domains
and required specialist equipment.
The Edmonton Frail Scale (EFS) is a simple to perform frailty assessment that comprises
of 10 questions and one physical assessment (‘timed up and go’). The EFS has been
validated against Comprehensive Geriatric Assessment (CGA), the current gold-standard
for frailty assessment, and shown to be reliable and feasible for routine use by non-geriatricians.[12]
Scores range from 0 (not frail) to 18 (very frail), with scores of 8 or above being
defined as frail. Dasgupta, et al.[13] described use of Edmonton Frail Scale (EFS)
on patients pre-operatively, in advance of elective orthopaedic operations. The study
found individuals with a score of 7 or more were likely to have increased post-operative
complications and less likely to be discharged home.[13] REFS is an adaptation of
EFS, that can be performed in less than 10 min by any healthcare professional.[14]
REFS substitutes the last domain on EFS, the physical performance measure, with three
self-assessed physical performance questions (Table 1). This is ideal for use in busy
cardiology clinics when patients are being assessed for suitability for intervention.
In addition, it is common for patients exercise ability to be affected by worsening
AS, and thus not perform as well in the physical assessment part of the EFS.[15]
Table 1.
Reported Edmonton frail scale, adapted from Hilmer, et al.[14]
Domain
Item
0 point
1 point
2 points
Cognition
Pre-drawn circle. Add the numbers in the correct positions to make a clock then place
the hands to indicate a time of ten after eleven
No errors
Minor errors
Major errors
General health
In the past year, how many times have you been admitted to a hospital?
0
1–2
> 2
In general, how would you describe your health?
Good/Excellent
Fair
Poor
Functional independence
With how many of the following activities do you require help? Meal preparation Shopping Transportation Telephone Housekeeping Laundry Managing
money Taking medications
0–1
2–4
> 4
Social support
When you need help, can you count on someone who is willing and able to meet your
needs?
Always
Sometimes
Never
Medication use
Are you on five or more different prescription medications on a regular basis?
No
Yes
At times, do you forget to take your prescription medications?
No
Yes
Nutrition
Have you recently lost weight such that your clothing has become looser?
No
Yes
Mood
Do you often feel sad or depressed?
No
Yes
Continence
Do you have a problem with losing control of urine when you do not want to?
No
Yes
Functional performance
Two weeks ago, were you able to:
Do heavy work around the house like washing windows, walls, or floors without help?
Yes
No
Walk up and down stairs to the second floor without help?
Yes
No
Walk 1 km without help?
Yes
No
Some clinicians might argue that frailty is something that can be diagnosed ‘from
the end of the bed’ or a quick glance. However, Hii, et al.[16] showed that there
was limited correlation between cardiologists attempting to diagnose frailty from
‘the end of the bed’, and that such an assessment was not a reliable way to determine
frailty.[16] To be able to use an objective and scored measure of frailty to aid the
TAVR assessment process and MDT discussions would be invaluable.
To date, there is currently no literature on the application of REFS to predict outcomes
of TAVR patients. Therefore, the purpose of this study was to evaluate the correlation
between frailty score using REFS and outcomes following TAVR, specifically mortality,
length of hospital stay and discharge destination.
Consecutive patients with severe symptomatic aortic stenosis referred for evaluation
at Imperial College NHS Trust, considered high risk for surgical aortic valve replacement
(SAVR), but eligible for TAVR were included. This group of high risk patients were
assessed in the TAVR clinic between March 2014 to July 2016. Following clinic each
patient was discussed in a MDT that consisted of interventional cardiologists, cardiothoracic
surgeons, anaesthetist, radiologists and a geriatrician. A consensus was reached amongst
the MDT about offering a TAVR. Patients were excluded if they had TAVR as an emergency
or they were not reviewed by the geriatrician undertaking the REFS prior to their
procedure. The REFS was performed with the patients and/or caregiver.
All patients had extensive cardiac baseline examinations including echocardiography
to evaluate left ventricular ejection fraction, aortic valve orifice area and mean
gradient, in addition to coronary angiography, CT angiography and lung function tests.
Symptomatic history was elicited including allocation to NYHA classification.
A Medtronic CoreValve or an Edwards Sapien XT bio-prosthesis was implanted. The transcatheter
aortic valve was introduced transfemorally whenever feasible, otherwise transapical
or subclavian routes were adopted.
The primary outcomes measured were length of hospital stay, 30-day mortality, 12-month
mortality, 18-month mortality and destination on discharge.
To analyse data, we used Chi-Square test for assessment of two categorical variables
and Mann-Whitney test for nonparametric variables. For all statistical analyses, we
used commercially available software (GraphPad Software).
Frailty assessment was performed on 62 patients with severe symptomatic aortic stenosis
between March 2014 and July 2016 who subsequently underwent TAVR. Mean age was 84
years (range 68 to 95) with 26 being females (42%). REFS ranged from 1 to 12, with
mean score of 6, mode 5, median 5 (Figure 1). Forty seven (76%) patients were deemed
not frail (score of 7 or less) and 15 (24%) frail (score of 8 or above). Demographics
and clinical characteristics were very similar between the frail and non-frail groups
(Table 2).
Figure 1.
Distribution of REFS scores.
Figure 2.
Mortality of non-frail and frail patients at 30-day, 12-months and 18-months.
Table 2.
Patient characteristics.
Non-frail, n = 47
Frail, n = 15
Male
27 (57%)
9 (60%)
Female
20 (43%)
6 (40%)
Age
85 ± 6
81 ± 4
Smoker/Ex-Smoker
19 (40%)
6 (40%)
Diabetes
9 (19%)
3 (20%)
Data are presented as mean ± SD or n (%).
Three (5%) patients died within 30 days of undergoing TAVR. Of these, two were non-frail
(4% of non-frail group) and one was frail (6% of frail group). Over the following
11 months, a further two patients died (one non-frail and one frail). After 18-months,
10 patients had not survived. Of these six were non-frail (13% of non-frail group)
and 4 frail (27% of frail group); chi-square 1.62, P-value 0.20 (Figure 2).
Mean length of stay (LOS) of the surviving to discharge patients (58 patients) was
8 days; range 1 to 22 days post procedure. Non-frail mean length of stay was 7 days
and frail group was 10; Mann Whitney U test with LOS: Z-score = –1.7444 (P = 0.04).
Fifty four of the surviving to discharge patients were discharged directly back to
their original place of residence, the other four were sent to rehabilitation either
at a local hospital or community facility. Of which, three were non-frail patients.
Whilst the concept of frailty and poor health outcome is well documented in the literature,
limited information is available relating to the practicability of frailty to predict
outcomes following TAVR.[8] This study identifies a statistically significant correlation
between REFS and LOS in patients who underwent TAVR. It did not confirm an association
with in-hospital, 12-month or 18-month mortality. Despite the patients being classified
as ‘high risk’ the vast majority (95%) survived to discharge, and were discharged
to their original place of residence. In particular, 52 (84%) patients were still
alive at 18 months post TAVR, despite being deemed too high risk for SAVR. This compares
favourably to outcomes observed in the original TAVR trials. Incorporating REFS into
the pre-operative assessment could be pivotal in helping run an efficient service
within the constraints of healthcare finance. Knowing that frailer patients are able
to undergo the operation with similar mortality but require longer hospital stay,
is important for patient choice, resource management and planning. The more intensive
use of therapists and specialist geriatricians may be able to help the discharge of
frailer patients, particularly when identified prior to admission.
On the basis of our observations described, our unit now routinely uses REFS as part
of the overall assessment of patients referred for TAVR, in conjunction with current
risk stratification scores and MDT assessment. The Montreal Cognitive Assessment,
anatomical considerations on the ease of performing TAVR versus SAVR, and patient
choice are all used in the final assessment to determine a definitive management plan.
This is a small sample from a single centre, but the data highlights a link between
length of stay following TAVR and frailty using REFS. In keeping with other studies,
there was an increase in longer term mortality in the frail group (13 vs. 27%, P =
0.2). However, this was not statistically significant, again, probably a reflection
of study size. The study did not follow up or further assess patients that did not
undergo intervention and received medical management alone. It is likely that this
group would have the highest mortality.
In conclusion, REFS demonstrates a simple, quick and free-to-use frailty score that
can be completed in less than a few minutes by any member of the team. A REFS score
of greater than seven identifies patients that are likely to experience longer hospital
stays. However, frailty should not be an obstacle to TAVR as their long-term survival
is better than those treated with medications alone. This score provides a quantifiable
measure of frailty to inform the MDT discussion when determining optimal management
strategies in the complex high-risk patient group.